Literature DB >> 33647187

Cardiac medication management in Duchenne muscular dystrophy.

Samuel G Wittekind1, Chet R Villa1.   

Abstract

There have been significant improvements in the skeletal muscle and respiratory care for patients with Duchenne muscular dystrophy (DMD) over the last two decades. This has resulted in longer expected survival as many patients will live into their 20s and 30s. This timeline has resulted in a greater proportion of patients experiencing heart failure and cardiac-related mortality. Herein, we describe the current indications for medical therapy for patients with DMD.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  Duchenne muscular dystrophy; heart failure; left ventricular dysfunction; neuromuscular disorders

Year:  2021        PMID: 33647187     DOI: 10.1002/ppul.25175

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  1 in total

1.  Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging.

Authors:  Abhinandan Batra; Alison M Barnard; Donovan J Lott; Rebecca J Willcocks; Sean C Forbes; Saptarshi Chakraborty; Michael J Daniels; Jannik Arbogast; William Triplett; Erik K Henricson; Jonathan G Dayan; Carsten Schmalfuss; Lee Sweeney; Barry J Byrne; Craig M McDonald; Krista Vandenborne; Glenn A Walter
Journal:  BMC Cardiovasc Disord       Date:  2022-06-09       Impact factor: 2.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.